Key result
Cancer in COVID-19 patients is linked to higher 30-day mortality and severely impaired heart function.
Why the study?
What are the clinical characteristics, risk factors, and cardiac manifestations of cancer patients with COVID-19?
Observational
What are the clinical characteristics, risk factors, and cardiac manifestations of cancer patients with COVID-19?
COVID-19 patients with cancer face higher mortality and significant cardiac and coagulation abnormalities, which are further exacerbated by underlying cardiovascular disease.
Answers are grounded in this paper and cite their sources.
May warrant closer cardiac monitoring in COVID-19 cancer patients; leaves open causal mechanisms and targeted interventions.
Our study indicates that the 30-day mortality is higher in COVID-19 patients with cancer; more COVID-19 patients with cancer are in severe and critical status; age, respiratory rate, neutrophil count, AST, BUN, MYO, Pro-BNP, disease severity status, underlying diseases, and fever are risk factors for in-hospital mortality among COVID-19 cancer cases; COVID-19 patients with cancer display severely impaired myocardium, damaged heart function, and imbalanced homeostasis of coagulation; what is more, those with both cancer and CVD have more significantly increased Pro-BNP and D-Dimer level.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted an observational in COVID-19 with cancer. Cancer vs. COVID-19 patients without cancer was evaluated on 30-day mortality. Cancer in COVID-19 patients was associated with higher 30-day mortality, more severe disease status, and severely impaired myocardium and heart function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: